sonoma pharmaceuticals, inc., develops and produces stabilized hypochlorous acid (hocl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the united states and internationally. the company offers epicyn, an antimicrobial facial cleanser; levicyn, a hypochlorous acid (hocl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; sebuderm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and ceramax, a lipogrid based skin barrier cream for management of dry itchy skin, minor skin irritations, rashes, and inflammation caused by various skin conditions, as well as loyon for the management of skin scal
Company profile
Ticker
SNOA
Exchange
Website
CEO
Amy Trombly
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Oculus Innovative Sciences, Inc.
SEC CIK
Corporate docs
IRS number
680423298
SNOA stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
9 Apr 24
8-K
Sonoma Pharmaceuticals, Inc. Investor Presentation April 2024
2 Apr 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
22 Mar 24
8-K
Entry into a Material Definitive Agreement
8 Mar 24
424B3
Prospectus supplement
8 Mar 24
10-Q
2024 Q3
Quarterly report
8 Feb 24
8-K
Sonoma Pharmaceuticals, Inc. Investor Presentation January 2024
10 Jan 24
8-K
Entry into a Material Definitive Agreement
9 Jan 24
8-K
Departure of Directors or Certain Officers
29 Dec 23
8-K
Entry into a Material Definitive Agreement
15 Dec 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Mar 23 | Mar 22 | Mar 21 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.14 mm | 2.14 mm | 2.14 mm | 2.14 mm | 2.14 mm | 2.14 mm |
Cash burn (monthly) | 469.00 k | 101.17 k | 432.67 k | 507.75 k | 410.33 k | 352.92 k |
Cash used (since last report) | 3.23 mm | 697.51 k | 2.98 mm | 3.50 mm | 2.83 mm | 2.43 mm |
Cash remaining | -1.10 mm | 1.44 mm | -846.11 k | -1.36 mm | -692.13 k | -296.26 k |
Runway (months of cash) | -2.3 | 14.2 | -2.0 | -2.7 | -1.7 | -0.8 |
Institutional ownership, Q2 2023
1.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 15 |
Opened positions | 2 |
Closed positions | 4 |
Increased positions | 0 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 134.97 mm |
Total shares | 161.91 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Two Sigma Securities | 52.04 k | $55.69 mm |
Geode Capital Management | 36.21 k | $39.47 mm |
STT State Street | 24.32 k | $26.50 mm |
Renaissance Technologies | 22.21 k | $24.00 k |
VIRT Virtu Financial | 14.73 k | $16.00 k |
Tower Research Capital | 8.58 k | $9.18 mm |
BLK Blackrock | 2.88 k | $3.08 mm |
USB U.S. Bancorp. | 500.00 | $535.00 k |
Advisor | 216.00 | $231.00 k |
MS Morgan Stanley | 86.00 | $92.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Dec 23 | Jerome J Dvonch | Stock option Common Stock | Grant | Acquire A | No | No | 0.18 | 60,000 | 10.80 k | 117,777 |
29 Dec 23 | Dal Poggetto John | Stock option Common Stock | Grant | Acquire A | No | No | 0.18 | 50,000 | 9.00 k | 55,000 |
29 Dec 23 | Amy Moss Trombly | Stock option Common Stock | Grant | Acquire A | No | No | 0.18 | 60,000 | 10.80 k | 173,648 |
29 Dec 23 | Bruce Thornton | Stock option Common Stock | Grant | Acquire A | No | No | 0.18 | 60,000 | 10.80 k | 176,781 |
News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
18 Apr 24
Sonoma Pharmaceuticals Announced The Expansion Of Its Microcyn Negative-pressure Wound Therapy (NPWT) Solution Products In The U.S.
9 Apr 24
12 Health Care Stocks Moving In Thursday's Pre-Market Session
28 Mar 24
Sonoma Pharmaceuticals Highlights Safety Advantages Of Microcyn Products
27 Mar 24
Sonoma Pharmaceuticals Q3 EPS $(0.08) Up From $(0.62) YoY, Sales $3.14M Up From $2.94M YoY
8 Feb 24
Press releases
Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United States
9 Apr 24
Sonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract Infections
4 Apr 24
Sonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other Topicals
27 Mar 24
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2024 Financial Results
8 Feb 24